The risk of invasive pneumococcal disease (IPD) persists beyond early childhood in HIV-infected children not receiving antiretroviral therapy (ART) [1] . The advent of pneumococcal conjugate vaccine (PCV) has been associated with 98% efficacy against invasive disease in the United States and with 73%-85% efficacy in Africa [2] [3] [4] . Unlike in the United States, studies from Africa did not include a booster dose of vaccine after a primary series of 3 doses during infancy.
The absence of a booster dose of vaccine may be especially pertinent in HIV-infected children, as shown by a reduction in vaccine efficacy against invasive disease from 65% at 2.3 years of follow-up to 38% at 5.3 years of follow-up [5] . Considering the progression of immunosupression in HIVinfected individuals not receiving ART, including the loss of memory lymphocytes, the immune response to a booster dose of vaccine in these children remains to be determined. Additionally, the current recommended dosing schedule for 7-valent PCV (PCV7) recommends a single dose of vaccine for healthy children aged 2-9 years [6] , the immunogenicity of which is uncertain in HIV-infected children.
The present study analyzed HIV-infected children and HIVuninfected children who had previously received 3 doses of either 9-valent PCV (PCV9) or placebo and aimed to compare the quantitative immune responses and opsonophagocytic activity to PCV7 five years after their primary vaccination series. An analysis of the proportion of these children with antibody concentrations that persisted above the putative threshold for protection against invasive disease, which was lower among HIVinfected children, has been published elsewhere [5] .
METHODS
Parents of children who had participated in a PCV efficacy trial were contacted by mail or identified at HIV clinics between March 2004 and April 2005 and were invited to have their children receive a dose of PCV7 (Prevnar). Initially, the invitation was independent of whether the child had previously received vaccine or placebo; however, logistical constraints resulted in only placebo recipients being targeted during the latter part of the campaign. Children (n ϭ 39,836) in the phase 3 trial had been individually randomized to receive 3 doses of either vaccine (containing 2 g each of serotypes 1, 4, 5, 9V, 14, 19F, and 23F polysaccharide; 2 g of serotype 18C oligosaccharide; and 4 g of serotype 6B polysaccharide [each conjugated individually to the protein CRM 197 ]) or placebo, concomitantly with other routine childhood vaccines, at 6, 10, and 14 weeks of age. None of the children received pneumococcal polysaccharide vaccine at any stage. Children who received all 3 doses of the study vaccine as per the study protocol during the efficacy trial were randomly screened for participation in the present study. Children for whom parental consent was received were administered a single dose of PCV7, which included all serotypes included in PCV9 except for 1 and 5. Clinical and laboratory staff remained blinded to the original randomization of the children in the phase 3 study. For the purposes of the present study, children who previously received 3 doses of PCV9 or placebo are referred to as "previous vaccinees" and "control subjects," respectively.
Venous blood was obtained from children before immunization at the time of the first visit and 4 weeks later. Blood samples were allowed to clot at room temperature before being centrifuged, and the serum was aliquotted and stored at Ϫ70°C until processing at the Respiratory and Meningeal Pathogens Research Unit (RMPRU), Johannesburg, South Africa. Vaccine serotype-specific capsular IgG antibody concentrations were measured at RMPRU by standardized EIA, incorporating adsorption with 10 g/mL pneumococcal C polysaccharide and 30 g/mL 22F polysaccharide [7, 8] . The calibrated standard serum 89-S was absorbed with 10 g/mL pneumococcal C polysaccharide [9] . Two internal controls were added to each plate: a high control consisting of pooled purified human IgG (Natal Bioproducts), and a low control consisting of a pool of in-house lowconcentration serum samples. The coefficients of variation (CV) for the high controls were 30%, 34%, 22%, 24%, 31%, 27%, and 37% for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, respectively. Antibody concentrations were calculated relative to the standard serum, using the US Centers for Disease Control and Prevention (CDC) program ELISA for Windows (version 2.15) [10] . For the calculation of geometric mean concentrations (GMCs), samples with values below the detection limit were assigned half the detection limit.
The functionality of the antibodies after vaccination was determined by opsonophagocytic killing assay using differentiated HL-60 cells for serotypes 6B, 9V, and 19F, as described elsewhere [11, 12] . For quality assurance, a quality control serum sample from a vaccinated volunteer was included on each plate. The CV of the control serum for each serotype was Ͻ30%.
Per 1994 CDC recommendations, the immunological status of HIV-infected children was categorized by stratifying the CD4 ϩ cell percentages into 3 groups: Ͻ15%, 15%-25%, and Ͼ25% [13] .
Data were analyzed using Stata software (version 8.0; StataCorp). The GMCs and 95% confidence intervals for serotypespecific capsular antibody and opsonophagocytic titers were calculated after log 10 transformation of the data. Comparisons of GMCs were performed using Student's t test on log 10 -transformed data.
A 2 test was applied for comparisons of proportions, and where appropriate Fisher's exact test was used for evaluating the difference between groups in the proportion of children with serum antibody concentrations 0.35 g/mL. It has been suggested that this threshold is a putative measure of immunity against serotype-specific IPD [14] . The concentration of antibody required for protection against other pneumococcal disease syndromes may, however, be higher.
The functionality of antibodies in serum samples was expressed as the opsonophagocytic titer, which is the reciprocal of the serum dilution determined to induce 50% killing of pneumococci. Continuous titers were determined by interpolating the concentration at which 50% killing of pneumococci occurred. If the maximum observed killing of pneumococci by HL-60 cells was Ͻ50% at the lowest dilution, the serum was assigned an arbitrary titer of 4. The concentration needed for 50% killing of pneumococci was determined by calculating the GMC of a newly created variable derived from dividing the serotype-specific antibody concentration of a sample by the serotype-specific continuous opsonophagocytic titer of the sample. The correlation between the serotype-specific anticapsular antibody concentrations and opsonophagocytic titers was measured using Spearman's correlation coefficients of log 10 -transformed data. Differences with an ␣ value of 0.05 were considered significant.
The present study was approved by the Human Subjects Research Committee of the University of the Witwatersrand. Written informed consent was obtained from the parents of the children.
RESULTS
Among the previous vaccinees for whom consent was initially granted, all 31 HIV-infected children and 89 (90.8%) of 98 HIVuninfected children returned after vaccination. Among the control subjects, 45 (91.8%) of 49 HIV-infected children and 110 (94.8%) of 116 HIV-uninfected children returned after vaccination. Only children completing both study visits were further analyzed, and their demographic information is shown in table 1. Vaccination occurred 5.3 (SD, 0.8) years after completion of the primary vaccination series. The mean time between the preand postvaccination blood sampling was 30.0 (SD 3.2) days. CD4 ϩ cell counts were available for 62 (81.6%) of 76 HIVinfected children. Compared with control subjects, HIVinfected previous vaccinees had a lower CD4 ϩ cell percentage and a trend toward a lower absolute CD4 ϩ cell count (table 1).
Only 15 (19.7%) of 76 HIV-infected children were receiving ART (table 1) .
Serotype-specific antibody concentrations before immunization with PCV7. Before immunization, previous vaccinees had higher GMCs than control subjects for all serotypes among HIV-uninfected children but for only 3 serotypes (6B, 14, and 19F) among HIV-infected children (table 2) . Furthermore, among previous vaccinees, the GMCs were lower for all serotypes among HIVinfected children compared with HIV-uninfected children (table  2) . For control subjects, GMCs were also lower for 4 serotypes (9V, 18C, 19F, and 23F) among HIV-infected children compared with HIV-uninfected children (table 2) .
Antibody responses after administration of PCV7. The changes in GMCs between baseline and 1 month after vaccination are detailed in table 2. For HIV-uninfected children, GMCs increased significantly after vaccination compared with baseline levels for all serotypes among previous vaccinees and control subjects (P Ͻ .001 for all serotypes). The magnitude of change in the GMCs were, however, greater in HIV-uninfected previous vaccinees than control subjects for 6 of the serotypes (4, 6B, 9V, 14, 18C, and 23F; P р .005) (table 2). For HIV-infected children, postvaccination GMCs were significantly greater than baseline values for all serotypes except 19F (P ϭ .13) among previous vaccinees and 6B (P ϭ .30) and 14 (P ϭ .29) among control subjects (table 2). The magnitude of change in GMCs was greater for only 3 of the serotypes (for serotype 4, P ϭ .05; for serotype 6B, P ϭ .003; for serotype 14, Table 1 . Demographic features of HIV-infected and HIV-uninfected children who received either a booster dose (previous vaccinees) or a first dose (control subjects) of pneumococcal conjugate vaccine (PCV) at 5 years of age. (%) of children, unless otherwise indicated. Previous vaccinees are children who received 3 doses of 9-valent PCV at 6, 10, and 14 weeks of age, and control subjects are children who received 3 doses of placebo at 6, 10, and 14 weeks of age. NA/ND, not applicable/not done. a CD4 ϩ cell results were available for 25 HIV-infected PCV recipients and 37 placebo recipients obtained within 6 months of visit 2. b P ϭ .03. c Thirteen children were receiving 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor, 1 PCV recipient each was receiving 3 NRTIs, and 1 was receiving a protease inhibitor and 2 NRTIs. P ϭ .03) among HIV-infected previous vaccinees compared with control subjects. Furthermore, postvaccination GMCs were significantly higher for all serotypes for HIV-uninfected children than HIV-infected children among previous vaccinees and control subjects.
The proportion of HIV-infected children with antibody concentrations 0.35 g/mL both before and after vaccination did not differ significantly for serotypes 6B, 14, and 19F among previous vaccinees and control subjects as well as for serotype 23F among previous vaccinees (table 3) . There was an increase in the proportion of children with antibody concentrations 0.35 g/mL for all serotypes among HIVuninfected previous vaccinees and control subjects (table 3) . Although a lower proportion of HIV-uninfected control subjects had antibody concentrations 0.35 g/mL for 5 serotypes (6B, 9V, 14, 19F, and 23F) (table 3) after vaccination compared with previous vaccinees, the overall proportion of control subjects with antibody concentrations 0.35 g/mL was Ͼ90% for all serotypes except 6B (73.6%).
Conversely, for HIV-infected children, vaccination induced serotype-specific antibody concentrations 0.35 g/mL in only 26.7% to 73.3% of control subjects and in 48.4% to 74.2% of Table 2 . Pre-and postvaccination geometric mean concentrations (GMCs) of antibody to individual pneumococcal vaccine serotypes, stratified by previous study-vaccine randomization and HIV status after receipt of a first vs. a booster dose of pneumococcal conjugate vaccine (PCV). NOTE. Antibody concentrations are shown in micrograms per milliliter; values in parentheses are 95% confidence intervals. Previous vaccinees are children who received 3 doses of 9-valent PCV at 6, 10, and 14 weeks of age, and control subjects are children who received 3 doses of placebo at 6, 10, and 14 weeks of age. The magnitude of the difference between pre-and postvaccination GMCs were significantly higher (P р .03) among HIV-uninfected children than among HIV-infected children for all serotypes among previous vaccinees and control subjects. previous vaccinees (table 3) . Antibody concentrations 0.35 g/mL were more frequent among HIV-infected previous vaccinees than control subjects after vaccination only for serotypes 6B and 14 (table 3) . HIV-infected children were less likely to have antibody concentrations 0.35 g/mL than were HIVuninfected children after vaccination (P р .003 for all observations) (table 3) among previous vaccinees and control subjects. When HIV-infected previous vaccinees or control subjects were stratified by CD4 ϩ cell percentage Ͻ15% vs. 15%, no differences were observed in GMCs between baseline and 1 month after vaccination or in the proportion of children with antibody concentrations 0.35 g/mL after vaccination (data not shown).
Opsonophagocytic activity after PCV7 vaccination. Opsonophagocytic killing assays were performed for all HIVinfected children with available samples and for 51 randomly selected HIV-uninfected previous vaccinees and control subjects. There were no differences in the baseline or postvaccine GMCs of antibody among HIV-uninfected previous vaccinees or control subjects between those for whom opsonophagocytic killing assays were performed and those for whom they were not (data not shown). 5 years of age among HIV-infected and HIV-uninfected  children who previously received either 3 doses of PCV (previous vaccinees) or placebo (control subjects) NOTE. Data are no. (%) of children, unless otherwise indicated. Previous vaccinees are children who received 3 doses of 9-valent PCV at 6, 10, and 14 weeks of age, and control subjects are children who received 3 doses of placebo at 6, 10, and 14 weeks of age. For the comparison of the proportion of children who had antibody concentrations 0.35 g/mL after vaccination, P р .003 for HIV-uninfected vs. HIV-infected control subjects, and P р .002 for HIV-uninfected vs. HIV-infected previous vaccinees.
a Prevaccination, before vaccination with 7-valent PCV (PCV7) at 5 years of age; postvaccination, 1 month after vaccination with PCV7 at 5 years of age.
b For the comparison between previous vaccinees and control subjects at the same visit. c For the comparison between before and after vaccination among children in the same group.
Detectable opsonophagocytic activity to serotype 6B was observed less frequently among HIV-infected control subjects (34.1%) than among HIV-infected previous vaccinees (74.2%) (table 4); however, control subjects required a lower concentration of antibody to achieve 50% killing than did previous vaccinees for serotype 6B (P Ͻ .001). Among HIV-infected previous vaccinees, detectable opsonophagocytic activity to serotype 19F (41.9%) was less common than that to serotype 6B (74.2%) (P ϭ .01); among control subjects, the prevalence of detectable opsonophagocytic activity was lower for serotypes 19F (36.4%; P ϭ .03) and 6B (34.1%; P ϭ .02) than for 9V (59.1%). HIVinfected previous vaccinees and control subjects were less likely to have detectable opsonophagocytic activity to the studied 3 serotypes than the respective groups of HIV-uninfected children (table 4) .
Opsonophagocytic titers of 8 were observed in the majority (88.2%-100%) of HIV-uninfected children and did not differ between previous vaccinees and control subjects for all 3 serotypes (table 4) . Pooling of data on previous vaccinees and control subjects among HIV-uninfected children showed that a greater proportion of children had detectable opsonophagocytic activity to serotype 6B (99 [97.1%] of 102; P ϭ .02) and serotype 9V (100%; P Ͻ .001) than to serotype 19F (90 [88.2%] of 102). The geometric mean titer of opsonophagocytic activity was higher among previous vaccinees for serotype 6B, did not differ for serotype 9V, and was lower for serotype 19F, compared with that among control subjects. The concentration of antibody required for 50% killing activity in the assay was, however, significantly lower for all 3 serotypes among HIV-uninfected control subjects than previous vaccinees as well as for serotype 6B among HIV-infected control subjects than previous vaccinees (table 4) .
The only differences between the proportion of children with an opsonophagocytic titer 8 and serotype-specific antibody concentrations 0.35 g/mL were for serotype 6B among HIVuninfected control subjects (96.1% vs. 74.5%; P ϭ .005) and for serotype 19F among HIV-infected control subjects (36.4% vs. 72.7%; P Ͻ .001). A significant correlation between antibody concentration (as measured by EIA) and opsonophagocytic activity was observed for serotype 6B among HIV-infected previous vaccinees (Spearman's ϭ 0.65; P Ͻ .001) as well HIV-infected and HIV-uninfected children after a booster dose (previous vaccinees) or  a first dose (control subjects) of pneumococcal conjugate vaccine (PCV) at 5 NOTE. Data are no. (%) of children, unless otherwise indicated. Previous vaccinees are children who received 3 doses of 9-valent PCV at 6, 10, and 14 weeks of age, and control subjects are children who received 3 doses of placebo at 6, 10, and 14 weeks of age.
a For the comparison between previous vaccinees and control subjects. b For the comparison between HIV-infected and HIV-uninfected previous vaccinees. c For the comparison between HIV-infected and HIV-uninfected control subjects. d Antibody concentration as measured by EIA among children for whom the OPA assay was done. e Geometric mean titer (GMT; i.e., reciprocal of the serum dilution determined to induce 50% killing of pneumococci) for OPA. f Antibody concentration needed for 50% of maximum uptake of labeled Streptococcus pneumoniae by HL-60 cells in the OPA assay.
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There was, however, a poor correlation between EIA-measured antibody concentration and opsonophagocytic activity for serotypes 9V and 19F among HIV-infected and HIV-uninfected children (P Ͼ .07).
DISCUSSION
ART reduces the incidence of opportunistic infections in HIVinfected children [15] ; however, individuals receiving ART still have heightened susceptibility to pneumococcal disease [16] . Our study predominantly involved HIV-infected children not receiving ART, similar to most countries with a high burden of HIV. The major findings include greater decay and, consequently, lower antibody concentrations 5 years after a primary series of PCV doses among HIV-infected children than HIVuninfected children. Furthermore, the immune response to a booster dose of vaccine in children previously primed with vaccine was lower in HIV-infected than HIV-uninfected children. Irrespective of previous priming with vaccine, HIV-infected children were also less likely to have functional antibody compared with the respective groups of HIV-uninfected children. Additionally, HIV-infected children receiving only a single dose of PCV had inferior immune responses compared with the counterpart HIV-uninfected children.
Our results are in agreement with those for 14 HIV-infected symptomatic Greek children vaccinated with 2 doses of PCV at a mean age of 10 years, among whom antibody concentrations were lower 12 months later compared with those among HIVnegative control subjects [17] . In contrast, a study using a formulation of PCV composed of a higher concentration of saccharide (10 g of each serotype) in toddlers [18] showed that the decline in antibody concentrations 8 months after a primary vaccination series was similar between 16 HIV-infected children and 14 HIV-uninfected children. The incomplete sustained immunity in our study emphasizes the need to evaluate whether HIV-infected children would benefit from booster doses of vaccine.
The T cell-dependent response to PCV should provide longterm protection against pneumococcal disease by inducing memory cell responses. An anamnestic immune response could then be stimulated on reexposure to vaccine epitopes through natural exposure, including nasopharyngeal colonization by vaccine serotypes or bacteria with cross-reactive epitopes, as well as with booster doses of vaccine. Among HIV-uninfected children, priming was associated with a more robust quantitative anamnestic response at 5 years compared with that induced solely by natural colonization among control subjects. This was evident in previous vaccinees having significantly higher GMCs after vaccination, greater fold increases in concentrations of antibody to most serotypes between pre-and postvaccine measurements, and a greater proportion of children with antibody concentrations 0.35 g/mL for 5 of the serotypes.
The differences in response to a booster dose of PCV between HIV-infected and HIV-uninfected previous vaccinees indicated relatively impaired anamnestic responses to vaccination among HIV-infected children. Additionally, the absence of any difference in GMCs for 4 serotypes and in the proportion of children with antibody concentrations 0.35 g/mL for 5 serotypes after vaccination between HIV-infected previous vaccinees and control subjects also indicated that priming with vaccine conferred an inconsistent immunological response advantage to subsequent vaccination. Robust memory responses were less evident among HIV-infected previous vaccinees than control subjects, among whom the magnitude of change between the pre-and postvaccination antibody concentrations was greater for only 3 of the 7 serotypes.
Although plasma HIV loads were not measured in our study (because none of the children were receiving ART during administration of the primary series of vaccine and only a minority subsequently received antiretroviral drugs), the majority of HIV-infected children probably had high HIV loads. The high HIV load may have contributed to the loss of memory cells or may have limited the initial memory cell induction, resulting from HIV viremia impairing interactions between B cells and CD4 ϩ cells [19] . A study in HIV-infected children receiving stable ART and with HIV loads Ͻ60,000 copies/mL showed that a baseline HIV load Ͻ400 copies/mL was associated with a better primary immune response and subsequent durability of antibody concentrations 1.5 years after a primary series of PCV doses [20] . It remains unclear from our study, in which a booster dose of vaccine was given 5 years after the primary series, whether earlier booster doses of vaccine may have sustained the memory responses in HIV-infected vaccinees.
The current recommendation for a single dose of PCV in previously unvaccinated healthy children between 2-9 years of age appeared to be adequate for HIV-uninfected control subjects; however, the proportion of HIV-infected control subjects who attained antibody concentrations 0.35 g/mL after the single dose of vaccine ranged from 26.7% to 73.3%. The proportion was lower for each of the individual serotypes compared with that among HIV-uninfected control subjects. Whether HIVinfected control subjects may have benefited from an additional dose of vaccine is unclear, because there is conflicting evidence regarding the advantage of additional doses of PCV in older HIV-infected children even in the presence of treatment with ART [17, 20, 21] . Although the findings of Abzug et al. [20] , who studied children receiving ART who had predominantly achieved virological suppression and were older than those in our study, suggested an improved immune response after a second dose of PCV, other studies have not shown any significant increases in antibody concentrations after repeat administration of vaccine [17, 21] .
Our study, although including a 22F adsorption step in the ELISA, evaluated immune protection using the more conservative threshold of 0.35 g/mL as a putative measure of protection against invasive disease because we had previously reported impaired antibody functionality in HIV-infected children [14, 22, 23] . In the present study, mirroring the lower proportion of HIV-infected children who had serotype-specific antibody concentrations 0.35 g/mL, an opsonophagocytic titer 8 was less likely to be detected in HIV-infected previous vaccinees and control subjects than in the respective HIV-uninfected groups for all 3 serotypes studied. Additionally, although a dose of PCV resulted in similar proportions of HIV-uninfected previous vaccinees and control subjects having detectable opsonophagocytic activity, HIV-infected control subjects were less likely than previous vaccinees to have detectable opsonophagocytic activity to serotype 6B after a single dose of vaccine.
Among HIV-uninfected children, priming with PCV was associated with reduced antibody-mediated killing activity by the booster (per gram of antibody) for all serotypes, as was also the case for serotype 6B among HIV-infected children. Possible explanations for this, which merit further investigation, include possible differences in IgG isotype and/or antibody avidity after PCV immunization between children initially primed to the polysaccharide through vaccination compared with those primed through natural nasopharyngeal colonization by the specific serotypes or other cross-reactive bacteria. Such differences may also explain the differences in results between the present study, in which the concentration of antibody required for 50% killing activity was similar for HIV-infected and HIVuninfected children, and the higher antibody concentrations required in HIV-infected children after following opsonophagocytic activity testing after the primary vaccination series [23] .
Assuming that an opsonophagocytic titer 8 is a more accurate putative measure of protection against IPD, similar to another study [22] , use of a serotype antibody concentration 0.35 g/mL would have underestimated the level of protection against serotype 6B among HIV-uninfected control subjects and overestimated protection against serotype 19F among HIVinfected children. This supports the notion that there may be variability in the threshold of antibody concentrations required for protection against invasive disease for different serotypes. Nevertheless, in general, there was a strong association between the proportion of children with antibody concentrations 0.35 g/mL and opsonophagocytic titers 8 for most of the studied serotypes among HIV-infected and HIV-uninfected children.
The poor correlation between antibody concentration and opsonophagocytic activity for serotypes 9V and 19F was in contrast to what was found 1 month after the primary series of PCV doses in the same community [23] . Although the exact reason for this remains to be determined, the poorer correlation between opsonophagocytic activity and antibody concentration among these older African children may be related to factors other than serotype-specific polysaccharide IgG antibody being more prevalent in older than in younger children.
Limitations of our study include the fact that anamnestic responses were not evaluated at earlier time points; hence, it is unknown whether the primary vaccination series had indeed induced memory responses in HIV-infected children. Additionally, because responses after vaccination were measured only 1 month later, the elicited immune responses may have been primary rather than exclusively indicative of anamnestic immune responses. Nevertheless, the diminished protection against invasive disease in the absence of a booster dose of PCV suggests that additional doses of vaccine are required in HIV-infected children immunized during infancy. The frequency and timing of additional booster doses of vaccine in HIV-infected children receiving ART need further characterization. Additionally, the optimal PCV regimen for HIV-infected immunocompromised children initially vaccinated after 2 years of age and living in areas in which the use of ART is limited needs to be ascertained.
